A case of lung adenocarcinoma harboring  mutation and fusion gene by unknown
Tanaka et al. BMC Cancer 2012, 12:558
http://www.biomedcentral.com/1471-2407/12/558CASE REPORT Open AccessA case of lung adenocarcinoma harboring EGFR
mutation and EML4-ALK fusion gene
Hisashi Tanaka1*, Akihito Hayashi1, Takeshi Morimoto1, Kageaki Taima1, Yoshihito Tanaka1, Michiko Shimada1,
Akira Kurose2, Shingo Takanashi1 and Ken Okumura1Abstract
Background: Lung cancer is the leading cause of cancer-related death worldwide. Epidermal growth factor
receptor (EGFR) - tyrosine kinase inhibitor (TKI) is used for the patients with EGFR-mutant lung cancer. Recently,
phase III studies in the patients with EGFR-mutant demonstrated that EGFR-TKI monotherapy improved
progression-free survival compared with platinum-doublet chemotherapy. The echinoderm microtubule-associated
protein-like 4 (EML4) - anaplastic lymphoma kinase (ALK) fusion oncogene represents one of the newest molecular
targets in non-small cell lung cancer (NSCLC). Patients who harbor EML4-ALK fusions have been associated with a
lack of EGFR or KRAS mutations.
Case presentation: We report a 39-year-old patient diagnosed as adenocarcinoma harboring EGFR mutation and
EML4-ALK fusion gene. We treated this patient with erlotinib as the third line therapy, but no clinical benefit was
obtained.
Conclusion: We experienced a rare case with EGFR mutation and EML4-ALK. Any clinical benefit using EGFR-TKI was
not obtained in our case. The therapeutic choice for the patients with more than one driver mutations is unclear.
We needs further understanding of the lung cancer molecular biology and the biomarker infomation.
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Lung cancer is the leading cause of cancer-related death
worldwide. Recent studies on personalized treatment by
selecting patients who are likely to respond to a particu-
lar therapeutic agent may allow improved treatment effi-
cacy. Patients with non-small cell lung cancer (NSCLC)
harboring mutations in the epidermal growth factor re-
ceptor (EGFR) gene have dramatic response to the
EGFR- tyrosine kinase inhibitor (EGFR-TKI) [1,2]. In
2007, the fusion of the anaplastic lymphoma kinase
(ALK) with the echinoderm microtubule-associated pro-
tein-like 4 (EML4) was identified in NSCLC. EML4-ALK
fusion gene arise as a result of an inversion in chromo-
some 2 that juxtaposed the 5 end of the EML4 gene with
the 3 end of the ALK gene. The frequency of the fusion
gene is approximately 6.7% in NSCLC [3]. The clinical* Correspondence: xyghx335@gmail.com
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reproduction in any medium, provided the orfeatures of lung cancer that harbors EML4-ALK include
light- or never-smokers, younger age, adenocarcinomas
with acinar pattern or signet ring adenocarcinoma, and a
lack of EGFR or KRAS mutations [4]. Patients who have
both mutations are extremely rare.
Case presentation
A 39-year-old man who is a light-smoker was referred to
our hospital in June 2009 because of an abnormal shadow
in the left upper field on chest X-ray (Figure 1A). Physical
examination revealed no significant abnormalities. Com-
puted tomography (CT) of the chest revealed a 40 mm
tumor in the left S1+2 with multiple lung and bone metas-
tases (cT4N3M1b). We conducted trans-bronchial lung bi-
opsy (TBLB). The pathological diagnosis of the TBLB
specimen was acinar adenocarcinoma (Figure 2A). In
immunohistochemistry (IHC) staining, transcription factor-
1 protein was positive. Laboratory findings were within nor-
mal range, except for the carcinoembryonic antigen (CEA)
level of 4.7 ng/mL (normal range, 0 to 4.3 ng/mL) in the
serum. We made a diagnosis of lung adenocarcinoma andLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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Figure 1 A. Chest radiography revealed a mass shadow in the left upper lung field. Figure 1B, 1C. Compared with the initial computed
tomography (CT) of thorax (B) and the repeated CT at 30 days after erlotinib treatment (C).
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ing cisplatin (80 mg/m2) and docetaxel (60 mg/m2) every
three weeks up to three cycles. However, no remarkable re-
sponse was observed. Therefore, the second line chemo-
therapy was conducted by pemetrexed (PEM) (500 mg/m2)
therapy. PEM therapy was effective, and fifteen courses of
PEM were administered to the patient. Thereafter new
bone metastatic lesions were appeared. The patient had
progressive disease (PD). We conducted re-biopsy to the
patient to check EGFR mutation analysis by cycleave
polymerase chain reaction technique (cycleave-PCR).
L858R point mutation (in which leucine at amino acidA
Figure 2 Histology of the primary tumor: (A) well differentiated aden
Immunohistochemical examination revealed that tumor cells were positive858 is replaced by arginine) was detected in the tumor
cell (Figure 3). Therefore we treated the patient with
erlotinib (150mg) therapy once a day. However, he had
disease progression after 30 days (Figure 1B, C). We
conducted the second re-biopsy to examine whether the
patient had ALK fusion gene. ALK fusion gene was
detected by reverse transcription polymerase chain reac-
tion (RT-PCR) method (Figure 4). Additionally, IHC
assay using a mouse monoclonal antibody for ALK anti-
body (Novocastra, Clone 5A4) revealed positive staining
(Figure 2B). ALK inhibitor could not be used to the pa-
tient because ALK inhibitor was not approved in JapanB
ocarcinoma component with acinar pattern (HE ×200). (B)
for monoclonal anti-ALK antibody (5A4) (×200).
Figure 3 EGFR-gene mutation (L858R point mutation) was showed positive by Cycleave-PCR method.
Figure 4 ALK fusion expression was showed positive by RT-PCR
validation.
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apy three cycles, the other metastases emerged in his liver,
and performance status became 3, therefore, palliative care
was administered to the patient in December 2011.
Discussion
We experienced a rare case of the patient who had both
EGFR mutation and EML4-ALK fusion gene. To the best
of our knowledge, five patients with both mutations have
been reported so far in the world [5-8]. Four patients
received EGFR-TKI therapy (Table 1). Two cases showed
good response [5,6], whereas the other two cases did not
[7]. We report the 5th case which also did not show good
response. In general, the response rate to EGFR-TKI ther-
apy in the patients with EGFR mutation is 70-80%, how-
ever, these 5 cases with both mutations tend to be less
responsive. In the preclinical study, EML4-ALK positive
NSCLC was not responsive to erlotinib therapy [9]. EGFR-
TKI therapy showed no effects to the all 10 patients with
EML4-ALK fusion gene [4], although, there were no
patients harboring both EGFR mutation and EML4-ALK in
these papers. Whereas, EML4-ALK positive patients had a
longer progression free survival after PEM therapy com-
pared with EGFR mutant patients [10].
In our case, the characteristics of the patient were young
age, light-smoker and acinar pattern adenocaricinoma
which showed similarity with the ones of EML4-ALK posi-
tive NSCLC. Additionally, PEM therapy showed a good re-
sponse to our patient, whereas erlotinib therapy did not. In
the cases with these both mutations, EML4-ALK gene may
play a main role in the oncogenesis for some unknown rea-
sons. Although ALK inhibitor was effective to EML4-ALK
positive NSCLC [11], it was not on the market in Japan at
that point. Further experience and the understanding of
the lung cancer molecular biology are required for thebetter treatment of the cases with both EGFR mutation
and EML4-ALK fusion gene.
Conclusion
We report a rare case of lung cancer harboring both
EGFR mutation and EML4-ALK fusion gene. PEM ther-
apy showed a good response to the patient, whereas
erlotinib therapy did not. Oncologists should be aware
of the possibility of the multiple mutations.
Table 1 Patients characteristics and treatment outcomes by EGFR-TKI
Citation Age Sex Smoking history Histology EGFR mutation EGFR-TKI response ALK variant
Kuo YW, et al. 72 Female Never Ad Exon19 deletion PR Variant 1
Potat S, et al. 65 Female Never Ad Exon19 deletion CR Unknown
Tiseo M, et al. 48 Male Never Adsq Exon19 deletion PD Unknown
Zhang X, et al. Unknown Female Never Ad Exon19 deletion NA Variant 3b
Present case 39 Male Former Ad L858R PD Variant 3b
Abbreviations.
Ad: adenocarcinoma, Adsq: adeno-squamous carcinoma, CR: complete response.
PR: partial response, PD: progressive disease, NA: not evaluated.
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for publication of this case report and accompanying
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